Discussion about this post

User's avatar
Steve Cheung's avatar

Very interesting to see that this trial included pts with “unstable” syndromes, yet only mandated DAPT for 8 weeks. And yet the 1 yr clinical secondary endpoints still favoured the DES arm (and presumably without increase in subacute stent thrombosis). This is a much shorter duration of DAPT than the current “standard DAPT” regimens esp for ACS….and even shorter than some of the “short DAPT” regimens that have been tested.

Expand full comment
Cardiology Trials's avatar

Hi Matt, this is just one of many trials we will review (and have already reviewed). It was not designed to address the questions you are raising but we have addressed those specific questions in other trials and on the podcast and will do so again in the future.

Expand full comment
2 more comments...

No posts